# Crystallization equipment for pharmaceutical APIs The stirred, draft-tube-baffled, melt and continuous crystallizers — plus the inline FBRM/PVM probes that close the loop on them — that turn a purified API molecule into a defined polymorph with a target particle-size distribution, the unit operation on which bioavailability, purity and downstream filterability all depend. Source: https://en.bioecon.ru/technology/crystallization-equipment-pharma-api/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: ICH Q8/Q9/Q10 & ICH Q13 continuous manufacturing | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] Crystallization equipment for pharmaceutical APIs is the set of vessels, coolers and continuous contactors that drive a purified active pharmaceutical ingredient out of solution into a solid crystal of defined polymorph, particle-size distribution and purity. It is the unit operation on which bioavailability, filterability and downstream drying all depend, and it is where the molecule becomes a processable solid. Three geometries dominate the field: batch draft-tube-baffled (DTB) and Oslo crystallizers for mid-volume APIs, plug-flow and MSMPR continuous crystallizers for high-volume steady-state production, and fractional-melt crystallizers for ultra-high-purity (electronic- or pharma-grade) isolation without solvent handling. The platform is mid-transformation along four axes: inline FBRM and PVM probes that close the loop on chord-length and crystal-shape in real time under ICH Q8 Quality-by-Design; the shift from batch to ICH Q13 continuous crystallization for high-volume APIs; automated parallel screening (Crystal16, Crystalline) that maps polymorph/solvent space in a single overnight run; and fractional-melt crystallization as a green, low-solvent purification route for high-value intermediates. The key directions of pharmaceutical crystallization equipment are: 1. **Automated parallel crystallization screening (Crystal16, Crystalline):** Technobis platforms that run 16 or 96 parallel small-volume crystallizations under software control, sweeping solvent, cooling rate and anti-solvent composition to map the polymorph/solvent landscape before scale-up. 2. **Industrial forced-circulation and draft-tube-baffled crystallizers (GEA Messo):** the mid-volume workhorse geometry — forced-circulation (FC), draft-tube-baffled (DTB) and Oslo growth-type crystallizers for steroid, vitamin and antibiotic APIs. 3. **Continuous and melt crystallization (Sulzer Chemtech):** plug-flow and MSMPR continuous crystallizers for steady-state ICH Q13 production, and fractional-melt crystallizers that exploit small impurity partition coefficients for electronic- and pharma-grade purity without solvent handling. 4. **Inline PAT and closed-loop control (Mettler-Toledo FBRM/PVM, ReactIR):** inline laser and video probes that track crystal chord-length, shape and supersaturation in real time, enabling Quality-by-Design closed-loop cooling under ICH Q8/Q9/Q10. ### Sectoral value chain ``` [API solution preparation] ──> [crystallizer (DTB / continuous / melt)] ──> [crystal suspension] │ (inline FBRM/PVM + supersaturation control) │ ▼ [dried API] <─── [drying] <─── [solid-liquid separation] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **API solution preparation** | dissolving the purified API in solvent or anti-solvent at set concentration and temperature | **In:** purified API, solvent. **Out:** clear API solution. | | **Crystallization** | cooling, anti-solvent, evaporative or melt-driven supersaturation in the crystallizer | **In:** API solution. **Out:** crystal suspension. | | **PAT & closed-loop control** | inline FBRM/PVM/ReactIR tracking chord-length and supersaturation for feedback cooling | **In:** crystal suspension. **Out:** controlled-size crystals. | | **Solid-liquid separation** | filtration or decanting of the crystal slurry from mother liquor | **In:** controlled suspension. **Out:** wet crystal cake. | | **Drying** | vacuum or conical drying of the wet cake to target residual solvent | **In:** wet cake. **Out:** dry API solid. | | **Polymorph & release QC** | XRPD, DSC and particle-size confirmation against the regulatory polymorph specification | **In:** dry API solid. **Out:** released API batch. | Cross-cutting technologies of the sector: - **Inline FBRM/PVM PAT (FBRM/PVM PAT):** focused-beam reflectance and particle-video microscopy probes for real-time chord-length and crystal-shape tracking. - **Continuous crystallization (Continuous Crystallization):** plug-flow and MSMPR geometries running at steady state under ICH Q13. - **Melt crystallization (Melt Crystallization):** fractional freezing for ultra-high-purity isolation without solvent handling. --- ## US The United States is the largest demand market for pharmaceutical crystallization equipment — most of the world's top-20 API manufacturers run US-based process-development and validation groups — and FDA's ICH Q8 Quality-by-Design and ICH Q13 continuous-manufacturing guidances are the regulatory drivers behind real-time FBRM/PVM closed-loop cooling and the batch-to-continuous transition. The crystallizer OEM base is European, so the US regional block describes the demand-and-adoption side rather than an indigenous OEM. ### ICH Q8 QbD adoption, continuous-manufacturing validation, process-development demand - **FDA ICH Q8/Q9/Q10 Quality-by-Design:** the framework that requires a defined polymorph control strategy and real-time release, pulling FBRM/PVM PAT into every new API filing. - **ICH Q13 continuous-manufacturing adoption:** US filers lead on continuous crystallization submissions for high-volume APIs, validating plug-flow and MSMPR geometries. - **US process-development demand:** the top-20 API manufacturers' US process-development groups are the primary buyers of Technobis parallel-screening and Mettler-Toledo automated-lab-reactor platforms. --- ## CN China is the fastest-growing production geography for pharmaceutical crystallization equipment: domestic API manufacturers supplying steroids, vitamins (ascorbic acid, B-group, D3) and antibiotics are scaling mid-volume DTB and Oslo crystallizer capacity, and NMPA's adoption of ICH Q8/Q9/Q10/Q13 harmonises the Quality-by-Design and continuous- manufacturing framework with FDA and EMA. The crystallizer OEM base remains predominantly imported (European), so the CN regional block is held qualitative. ### API scale-out, NMPA ICH Q8/Q13 alignment, imported OEM base - **Domestic API production scale-out:** steroid, vitamin and antibiotic manufacturers run mid-volume DTB and Oslo crystallizer trains built around European (GEA, Sulzer) and PAT (Mettler-Toledo) hardware. - **NMPA ICH Q8/Q9/Q10/Q13 alignment:** harmonised Quality-by-Design and continuous-manufacturing guidance, framing the regulatory route for FBRM/PVM closed-loop and continuous crystallization. - **Imported OEM base:** the crystallizer and PAT OEM layer is predominantly European; domestic firms localise media, solvent recovery and downstream drying rather than the crystallizer itself. --- ## EU Europe is the centre of pharmaceutical crystallization equipment manufacturing — all four crystallizer OEM classes and the dominant PAT platform are European. Technobis (Alkmaar, NL) builds the automated parallel-screening platforms; Sulzer Chemtech (Winterthur, CH) builds continuous and fractional-melt crystallizers; GEA Messo builds the industrial DTB, Oslo and forced-circulation workhorses; Syrris (Royston, UK, an Agilent company) supplies flow-chemistry and continuous-crystallization platforms; and Mettler-Toledo supplies the FBRM/PVM/ReactIR PAT suite. EMA's ICH Q8/Q13 implementation completes the framework. ### crystallizer OEMs, PAT platforms, EMA ICH Q8/Q13 - **Technobis — Crystal16 & Crystalline:** automated parallel crystallization screening platforms mapping polymorph and solvent space across 16–96 small-volume vessels. - **Sulzer Chemtech — SuPro & melt crystallizers:** plug-flow continuous crystallizers and fractional-melt units for electronic- and pharma-grade purification. - **GEA Messo — DTB, Oslo, FC crystallizers:** the industrial forced-circulation, draft-tube-baffled and Oslo growth-type workhorses for steroid, vitamin and antibiotic APIs. - **Syrris — Asia flow-chemistry/crystallization (Agilent):** continuous-flow and batch-crystallization platforms for hazardous-reaction scale-up. - **Mettler-Toledo — FBRM, PVM, ReactIR:** the inline PAT suite (focused-beam reflectance, particle video microscopy, mid-IR) that closes the crystallization control loop under ICH Q8. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Technobis** | 🇳🇱 Netherlands | *Crystal16, Crystalline MS, PolyBlock* | Automated parallel crystallization screening (16–96 vessels) for polymorph/solvent mapping | Commercial | | **Sulzer** | 🇨🇭 Switzerland | *SuPro continuous, melt crystallizers* | Plug-flow continuous and fractional-melt crystallization for pharma/electronic-grade purity | Commercial | | **GEA Group** | 🇩🇪 Germany | *GEA Messo DTB, Oslo, FC crystallizers* | Industrial forced-circulation, draft-tube-baffled and Oslo growth-type crystallizers | Commercial | | **Syrris** | 🇬🇧 United Kingdom | *Asia flow chemistry, batch crystallization* | Continuous-flow and batch-crystallization platforms (Agilent company) | Commercial | | **Alfa Laval** | 🇸🇪 Sweden | *Crystallizer heat transfer & MAB* | Plate-and-shell heat exchangers and separation for crystallizer duty | Commercial | | **Mettler-Toledo** | 🇨🇭 Switzerland | *FBRM, PVM, ReactIR* | Inline PAT suite (focused-beam reflectance, particle video, mid-IR) for closed-loop control | Commercial | --- ## Tech stack and innovations The stack combines the crystallizer vessel, the inline PAT probes and the Quality-by-Design control strategy into one closed, validated process. 1. **Crystallizer geometries (Crystallizer Geometries):** - batch draft-tube-baffled (DTB) and Oslo growth-type crystallizers (GEA Messo) for mid-volume APIs; - plug-flow and MSMPR continuous crystallizers (Sulzer SuPro) for steady-state ICH Q13 production; - fractional-melt crystallizers for ultra-high-purity, low-solvent isolation. 2. **Inline PAT probes (Inline PAT Probes):** - FBRM (focused-beam reflectance) tracking crystal chord-length distribution in real time; - PVM (particle video microscopy) imaging crystal shape and habit; - ReactIR mid-IR tracking solution concentration and supersaturation for feedback cooling. 3. **Parallel screening & QbD control (Parallel Screening & QbD Control):** - Technobis Crystal16 / Crystalline parallel platforms sweeping solvent and cooling-rate space overnight; - Quality-by-Design cooling profiles under ICH Q8 that hold the process inside the design space for polymorph control. --- ## Value chains and production pipelines ### Industrial pipeline of a pharma-API crystallization train (ICH Q8/Q13) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. API solution prep │ ───> │ 2. Crystallization │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Solid-liquid separation│ <─── │ 3. PAT closed-loop control│ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Drying │ ───> │ 6. Polymorph & release QC │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: API solution preparation The purified API is dissolved in solvent or anti-solvent at a set concentration and temperature to give a clear, undersaturated starting solution. #### Stage 2: Crystallization Supersaturation is generated — by cooling, anti-solvent addition, evaporation or melt — in the crystallizer (DTB, Oslo, FC, plug-flow or melt), nucleating and growing crystals to a target polymorph and size. #### Stage 3: PAT closed-loop control Inline FBRM tracks crystal chord-length, PVM images crystal habit and ReactIR tracks supersaturation, feeding a Quality-by-Design cooling profile under ICH Q8 that holds the process inside the design space. #### Stage 4: Solid-liquid separation The crystal slurry is filtered or decanted from the mother liquor on a filter dryer or pusher centrifuge, yielding a wet crystal cake. #### Stage 5: Drying The wet cake is dried under vacuum or in a conical dryer to the target residual-solvent specification set by ICH Q3D. #### Stage 6: Polymorph and release QC X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and laser particle-size analysis confirm the polymorph, habit and size distribution before batch release against the regulatory specification.